INTRODUCTION: ARE AGING MEN THE NEW WOMEN?
In the spring of 2002, the Women's Health Initiative prematurely terminated a long-term study on the risks and benefits of hormone replacement therapy (HRT) in postmenopausal women.
1 Apparently, not only did HRT not deliver on the benefits that it had promised, but it also increased the risk of cardiovascular events and breast cancer (Day 2002) . Feminist critics of the medicalization of menopause and the promotion of HRT had long taken issue with what they saw as a patriarchal medical establishment's conceit in seeking to chemically remake aging women according to sexist, ageist standards. Now, it seemed they were vindicated in their belief that HRT had been a mass experiment on women's bodies all along (Seaman 2003) . At the same time, there was a surge of scientific and commercial interest in promoting the male menopause as a clinical disorder that could be appropriately treated with hormone replacement-in this case, testosterone. Apparently undeterred by mistakes made in the medicalization of women's menopause, where "on the basis of questionable evidence and scientific fallacies . . . many extravagant claims were made about the wonders of estrogen replacement" (O'Donnell et al. 2004, 975) , a full-scale attempt to medicalize the "male menopause"-and treat it with testosterone-was underway by end of the twentieth century. A large body of critical literature has now exposed the menopause in women as a social construction-one that is heavily medicalized in Western societies (Bell 1987; Kaufert and Lock 1997) and complexly linked to commercial interests (Dukes 1997; Palmlund 1997) . A similar critique of the social construction and medicalization of the male menopause is now overdue.
As a contribution to this critique, this article explores the history and contemporary construction of the male menopause as a clinical disorder. After a brief review of early medical opinions on the climacteric and sexuality, I recount the antecedents of hormonal antiaging therapies in the rejuvenation experiments of the late nineteenth and early twentieth centuries and the mainstream medical take-up of testosterone therapy in 1930s and 1940s. I then show how the ambivalence toward the sexual rejuvenation of aging men that was apparent in these contexts was overcome in the late twentieth century, especially as the success of Viagra gave new impetus to the medicalization of male sexuality in later life (Carpiano 2001; Loe 2001; Marshall 2002; Potts et al. 2004 ). This is demonstrated by an analysis of the recent construction of a robustly medicalized understanding of male aging and sexuality via the "andropause," or "androgen deficiency in the aging male"-a reversible state of testosterone deficiency for which most, if not all, aging men are considered to be at risk. I review both the clinical and the popular literatures to demonstrate the convergence of scientific and commercial interests in medicalizing masculinity in later life. 2 In conclusion, I suggest that shifting cultural narratives of aging and sexuality are central in understanding how the aging male body has been constructed as a site of biomedical explanation. I argue that we need to be more attentive to the role of age in formations of hegemonic masculinities and to the manner in which these are configured by the new biology of the body that has emerged in relation to pharmaceutical therapies and consumer lifestyles geared toward functionality and performance. Skae (1865) expanded the symptomology of the male climacteric to include sexual decline but posed this as a moral rather than a physical problem, one requiring adjustment to the inevitable loss of sexual powers.
While still assuming a natural relationship between aging and sexual decline, Victorian narratives of the "spermatic economy" (Haller 1989) held that masculine sexual vitality was a fixed resource linked to semen supply. If managed prudently, it could be enjoyed into late life, but if poorly managed, sexual decline could occur at any age. It was not until the early twentieth century, as the midlife was identified as a time ripe for therapeutic and moral intervention, that the notion of age-related midlife sexual decline took hold (Gullette 1994 Know (1901) is a classic example of the middle-aging of decline that began at the turn of the twentieth century. Linking sexual loss to middle age, Stall suggested that it was nature's course to diminish sexual power in men once their peak reproductive fitness had passed. He reminds his readers of the benefits of accepting and adjusting to sexual decline, promising that "the stress of passion will be past, the imagination will become more chastened, the heart more refined, the lines of intellectual and spiritual vision lengthened, the sphere of usefulness enlarged" (Stall 1901, 59 ).
The conviction that men's sexual powers naturally declined with age could lead only to a counsel of acceptance. Advice similar to Stall's was widely repeated in the literature of the time. As Sturgis wrote in 1931, "Where old age is the cause of impotence, there is, alas! no remedy, except to submit as gracefully as possible to the decrees of fate, and by carefully husbanding the sexual resources to prolong the usefulness of the genital organs as far as possible" (Sturgis 1931, 312) . However, those who contended that the secret to masculine vitality-and the secret to forestalling its loss in the aging process-lay in the sex glands themselves rejected this advice. There is certainly a long-standing belief that masculine virility, valor, and vigor are rooted in the testes, but nowhere was the assumption of a testicular basis to masculinity more clear than in the organotherapy and rejuvenation experiments of the late nineteenth and early twentieth centuries. As Sengoopta put it, "The gland became a clinical superstar" (Sengoopta 2001, 643) .
SEX GLANDS AND REJUVENATION
Charles Edouard Brown-Séquard created a stir when, in 1889, at the age of seventy-two, he injected himself with a potion distilled from crushed dog testicles and reported that it had resulted in the renewal of his physical and mental vigor. While the mainstream medical community did not react with enthusiasm, Brown-Séquard was but one in a line of rejuvenation scientists who, in different countries and over the next half century, attempted to demonstrate that the testicle held the key to youthful and masculine vitality (Hirshbein 2000; Scott 1953; Trimmer 1967) .
Sengoopta calls the 1920s the "decade of the testicle," as it was then that "physiological and clinical research on testicular functions came together in what, for a time, seemed to be a spectacularly successful synthesis" (Sengoopta 2001, 644) . In Russia, Serge Voronoff gained international attention (and notoriety) for his experiments grafting monkey testicles onto humans (Hamilton 1986) . Austrian scientist Eugen Steinach also experimented with testicular transplants but became best know for the "Steinach operation"-essentially a vasectomy-which supposedly let the body reabsorb testicular fluid instead of discharging it and hence reap the benefit of its invigorating power (Sengoopta 2003) . By the 1920s, a number of scientists, like Harry Benjamin and Peter Schmidt, had taken up Steinach's theories and were conducting their own trials with surgical rejuvenation (Schmidt 1929 ). Steinach's theory of sex hormones was rooted in a rigid binary of masculine and feminine. Thus, he held that "the sex hormone is not only sex-specific, but counter-specific . . . it operates as a barrier to characters of unlike sex, thus assuring, under natural conditions, the principle of normal differentiation between male and female" (Steinach and Loebel 1940, 20) . As further testament to the extent to which masculinity was thought to be rooted in the testicle, Steinach hypothesized that homosexuality was due to gonadal deficiency and devised a treatment for homosexual men entailing the transplantation of a testicle from a heterosexual. As Sengoopta comments, this was predictably ineffective but "clearly demonstrates the narrow biologistic principles with which Steinach sought to intervene in the complex world of human sexuality" (Sengoopta 2003, 123) .
Much of the motivation for the rejuvenation of aging men revolved around worries about declines in masculine productivity-while restoration of sexual function was part and parcel of the rejuvenation promise, this occurred primarily through its link with the general capabilities of the vital, youthful man. Steinach himself stressed both the physical disorders that plagued the aging man (e.g., cancer, heart disease, and hypertension) and the "paralyzing fatigue, disinclination to work, failing memory, indifference and depression, all of which hinder or preclude progress and every kind of competition" (cited in Hirshbein 2000, 285) . Because it was the "sex gland" that provided the impetus for rejuvenation, casting a pall of immorality about the enterprise, its defenders downplayed sexual rejuvenation, instead emphasizing other benefits: "If reawakened manhood, a by-product of rejuvenation, occasionally is criticized as an immoral disadvantage of rejuvenation as a whole, then the simultaneously reawakened love of, and ability to work, should be considered a sufficient compensation" (Kammerer 1924, 185 ). Yet the association of rejuvenation with the restoration of sexual function continued to hamper its acceptance by mainstream medical practice. As Jaheil argues, American Medical Association president Morris Fishbein's hostile critiques of rejuvenation therapy, alongside other practices on the fringes of medical practice, "made it clear that there is something fundamentally distasteful about the very idea of an active sex life for the elderly" (Jaheil 1992, 30) .
The cultural significance of organotherapy and rejuvenation far exceeds their limited success as a clinical practice-after all, relatively few men actually underwent the procedures, and what success those who did may have claimed is now suspected to be largely a placebo effect (Cussons et al. 2002) . By the 1930s, surgical rejuvenation was discredited as a medical practice and consigned to the category of quackery by the medical establishment.
3 Yet the imagination of both the scientific community and the public was captured by the idea that science could forestall, or even reverse, the effects of age on the body (Hoberman 2005; Squier 1999 ).
MAINSTREAM MEDICINE AND THE MALE CLIMACTERIC
Construction of the male climacteric as an organic and treatable disorder began in earnest in the late 1930s and early 1940s with the publication of a number of articles in American medical journals. August Werner is generally credited with reintroducing the concept of the male climacteric to mainstream American medicine in 1939, suggesting that "it seems reasonable to believe that many, if not all, men pass through a climacteric period somewhat similar to women" and that "the true climacteric is due primarily to decline of function of the sex glands" (Werner 1939 (Werner , 1441 . Inspired by a 1942 call by the American Medical Association for rational scientific study into the male climacteric, the Journal of the American Medical Association published several articles on the treatment of climacteric symptoms by injection of testosterone (Heller and Myers 1944; Werner 1945 Werner , 1946 . Thus began what medical researchers saw as an era of rational biomedical intervention into the climacteric disease. Significantly, however, climacteric hypogonadism-the clinical disorder caused by low testosterone-was considered to affect a relatively small proportion of aging men. For example, researchers Heller and Myers (1944) , while advancing some clinical criteria for the diagnosis of the climacteric and reporting success with its treatment with testosterone, concluded that "whereas in the female the menopause is an invariable and physiologic accompaniment of the aging process, in the male the climacteric is an infrequent and pathologic accompaniment of the aging process . . . affecting only a small proportion of men who live into old age" (p. 477).
The association between the climacteric and sexual decline remained problematic. In 1946, August Werner confidently reasserted that it was an "established fact" that "man is subject to varying degrees of sexual function and does have a climacteric" (Werner 1946, 188) . However, Werner was just as insistent that while sexual dysfunction was a key symptom of the climacteric, it was not the main concern in treating it. He reiterated that sexual rejuvenation was not the aim of testosterone therapy with older men, arguing that "if this was the object of treatment, disappointment will result" (Werner 1946, 194) . Although potency might be inadvertently stimulated by testosterone therapy, Werner insisted that it should not be given for this purpose and suggested that "it is perhaps better for older men if this phase of the reaction does not result" (Werner 1945, 710) . In his discussion of this paper, Dr. Charles Dunn reiterated that "the male climacteric is an important syndrome because it occurs chiefly in men with important responsibilities, men who require sustained energy, physical and mental throughout the day to perform competently their assigned responsibilities… The true climacteric patient is more concerned with constitutional rehabilitation than he is with sexual stimulation" (Dunn 1945, 710) . As John Hoberman (2005, 8) notes, the "belief that testosterone was a sexually stimulating drug made it a potential threat to sexual morality as well as a promising therapy." Clearly, if testosterone replacement therapy hoped to move into the mainstream of medical practice, there had to be continued insistence on its nonsexual benefits.
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The ambivalence toward the importance of sexual function in debates about the male climacteric anticipated the crossroads at which the sciences of aging and sexuality would find themselves in the mid-twentieth century. The new emphasis on vitality, activity, and independence in gerontology, which posed such a challenge to traditionally negative stereotypes of later life (Katz 1996) , seemed stymied by the legacy of physiological explanations of sexual decline as an essential feature of a climacterized middle age. To an extent, this dilemma was resolved through shifting paradigms of psychological versus organic explanations of sexual decline (Marshall and Katz 2002) . Aging men were increasingly told that it was their anxiety over their supposed loss of sexual function, their fear of loss of potency that was causing their premature sexual decline. By the 1960s, two axioms characterized the advice given to men regarding sexuality and age: first, that psychological factors were primarily responsible for loss of sexual function, and second, that to cease having sex itself would hasten aging. The passive acceptance of age-related changes in sexual capacity that had characterized past professional advice now became viewed as a pathological adaptive strategy rooted in ignorance.
The idea of a male menopause, climacteric, or andropause remained contested throughout most of the remainder of the century, gaining more attention in popular advice books than in the medical or clinical community. Rather than a medical disorder, it was generally approached as a period of psychological or emotional upheaval, a "midlife crisis," or perhaps more accurately, a "change of life." As an article aimed at helping physicians treat their older patients put it, "The male menopause is a term that should never have been coined, yet it is with us for some time to come. It has no physical basis. It does not mark the stopping of sperm formation or of male hormone production. Instead, it is an emotional-attitude change" (Rutherford and Rutherford 1965, 223-24) . Ironically-at least from the perspective of those such as Werner-it took the placement of sexual function and its restoration back at the center stage of men's midlife problems to revitalize the concept of male menopause as a medical disorder in the late twentieth century.
REINVENTING THE MALE MENOPAUSE: SEXUALIZING MIDDLE AGE
In their review of professional and lay concern with what had, by the mid1980s, been termed "male menopause," Featherstone and Hepworth (1985, 236) note that at this time, there were "few, if any, researchers, writers or commentators who support belief in the existence of a male hormonal 'change of life' equivalent to that found in women." Couched in the general language of crisis, the popular portrayal of male midlife "change" involved not only work, status, and family but also sexuality. Featherstone and Hepworth locate the intensification of the sense of crisis in the sexualization of lifestyles among older age groups and the consequent incorporation of this trend by consumer culture. While the de-sexualization of the postmenopausal years for women was challenged first, both politically by feminism and by a range of commercial interests, Featherstone and Hepworth contend that by the mid-1980s, a similar shift in attitudes toward late-life male sexuality was underway. At the same time, they identify a number of social pressures-from changing family patterns to feminism to earlier retirementthat impinge upon conventional understandings of masculinity and sexual identity in midlife and after. For all of these reasons, they suggest that "the term male menopause is a particularly convenient way of expressing a personal and collective awareness of the subtle relationships in our culture between the aging process, sexual identity and lifestyle" (p. 243). However, it is precisely the anxiety over aging and masculinity captured by the "crisis" language of the male menopause that grounds its more recent medicalization. As Hepworth and Featherstone (1998) recognize in a later article, "medical and cultural entrepreneurs who have a stake in the emergence and legitimation of new conditions such as the male menopause" have been instrumental in blurring the boundaries between the midlife crisis as a psychological event and male menopause as a biological process.
Renewed interest in identifying a hormonal basis for a male menopause was evident by the mid-1990s, both in clinical research (Morley et al. 1994; Oddens and Vermeulen 1996; Tenover 1997) and in mainstream media stories touting the antiaging effects of testosterone for men (Cowley and Kalb 1996; Gutfeld 1994) . However, Oudshoorn (1997) argues that circumstances similar to those surrounding the initial development of male hormone therapy in the 1930s still persisted, which would continue to undermedicalize the male menopause. Specifically, she cites men's more passive attitudes toward seeking treatment for health problems and the continued marginalization of men's health in the organizational structures of institutionalized medicine as key factors. In other words, "health problems can only be classified as illness and be medicalized if there exists a cultural climate and a medical infrastructure that actively transforms health complaints into diseases. . . . The question therefore is not whether there exists such a thing as the male menopause, but whether the male menopause is actively called into existence by relevant social groups and patients" (Oudshoorn 1997, 143, emphasis added) . In the remainder of this article, I argue that both the cultural climate and the medical infrastructure have changed dramatically since Oudshoorn's article was published and in such a way as to "actively call into existence" the male menopause. Specifically, the clinical and market success of Viagra, introduced to the North American market in 1998, was pivotal in creating new institutional structures and health promotion discourses around men's sexual health and in constructing the aging male body as a site of biomedical intervention-in short, in medicalizing masculinity in middle and later life.
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ADAM AND ANDROPAUSE: CONSTRUCTING A DISORDER
While medical science has demonstrated sustained interest in hypogonadism and its treatment with testosterone, there are only scattered references to male menopause as a treatable disorder in the scientific literature published between 1950 and 1980.
6 As a crude measure of interest, a search in Medline (a search engine that indexes medical journals) using male menopause, andropause, and/or male climacteric as keywords shows a few articles appearing in the 1980s and 1990s, with 1998 as the first year with more than five citations. By 2003, there were twenty-nine citations. By the early years of the twenty-first century, mainstream journals, especially those focused on urology and impotence research, were peppered with articles bearing such titles as "Is It Andropause? Recognizing Androgen Deficiency in the Aging Male" ( However, there is a significant gap between andropause as a symptom complex and androgen deficiency-or hypogonadism-as a biochemical state. The renewed interest in medicalizing the "andropause" as "androgen deficiency" exemplifies what Peter Conrad has described as "shifting engines of medicalization," which "are now driven more by commercial and market interests than by professional claims-makers" (Conrad 2005, 10) . Because testosterone is only approved in the United States for the treatment of hypogonadism (not andropause per se), there is a major commercial motive in construing andropause as a form of hypogonadism. Hypogonadism itself is a relatively rare condition-there is, however, a very large and growing number of men in the over-fifty age group. Looking at the growth of prescriptions for testosterone supplements, it would appear that this has been a successful strategy. Citing data from IMS Health Inc., Tan and Culberson (2003, 18) report an overall increase of 500 percent in testosterone prescriptions since 1993. In just five years (1997) (1998) (1999) (2000) (2001) (2002) , testosterone prescriptions dispensed in the United States increased by more than 400 percent, with most of this increase in the form of newer, transdermal products. Reviewing prescription data also suggests that medicalizing male menopause has meant medicalizing middle age: according to two reports cited by the National Institute of Medicine, most testosterone prescriptions were given to men in the forty-five to sixty-five age group (Liverman and Blazer 2004, 25) .
In general, the assessment of research on andropause and its treatment with testosterone has not been positive. In addition to a number of individual studies finding no relationship between testosterone levels and clinical symptoms of hypogonadism in older men (Christ-Crain et al. 2004; McKinlay, Longcope, and Gray 1989; O'Donnell et al. 2004; T'Sjoen et al. 2004) , several meta-analyses of research studies on testosterone replacement therapy with older men have criticized the quality of research conducted. 8 In summarizing the scientific literature on male menopause, it is apparent that there is more disagreement than agreement on definition, diagnosis, and treatment. Researchers and clinicians generally agree that many older men report symptoms such as erectile dysfunction, decline in libido, and decrease in strength and energy. They also agree that there is a moderate and gradual decline in testosterone levels as men age but that many men remain well within the "normal" range for younger men. More contentious are issues such as whether declining testosterone levels have clinical significance, whether they may be caused by confounding factors such as obesity or inactivity, whether testosterone supplementation results in clear benefits, and if so, whether they outweigh the risks (Asthana et al. 2004 ). Comprehensive reviews of the research have concluded that "the strongest scientific evidence to date does not support a biological menopause in men" (Metz and Miner 1995, 302) , that there is insufficient evidence that "the modest decreases in circulating blood testosterone levels which commence during mid-life have any clinical importance" (Conway et al. 2000, 220) , and that the "growth in testosterone's reputation and increased use . . . has outpaced the scientific evidence about its potential benefits and risks" (Liverman and Blazer 2004, 11) .
How, then, does the mass of contradictory scientific evidence for the existence of, or appropriateness of hormone treatment for, a biologically based male menopause get translated into such confident affirmative statements in both the clinical and the popular literatures? It seems to be papering over a good deal of scientific controversy to assert that "a consensus has emerged that . . . the andropause is a fact, not a fiction" (Nicholls 2003, 99) or that "andropause is a testosterone deficiency that develops gradually over a number of years in all men aged 50 and over. Andropause can be treated with TRT [testosterone replacement therapy]" (Anderson et al. 2002, M796) . As with the creation of other disorders and the promotion of treatments for them, there is a convergence of scientific and commercial interests. The postViagra erectile dysfunction industry expanded the range of institutional and discursive structures that could not only accommodate but also nurture the medicalization of the aging male body (Baker 2001) . Professional associations, journals, conferences, and clinics focusing on men's sexual health and aging have proliferated. The pharmaceutical industry has worked hard to legitimate and publicize the disorders for which they have a treatment by sponsoring and disseminating research favorable to their products, as well as engaging in disease-awareness campaigns with the public (Moynihan and Cassels 2005) . The message, at least since the late 1990s, is that andropause is an age-related, hormone-deficiency disease for which most, if not all, men are at risk.
To unpack the promotion of this new story of male menopause in its latest reincarnation as androgen deficiency, let us start with "Roy's story," which appears on several Web sites and brochures (all of which seem to originate with Organon, makers of Andriol, a testosterone supplement): 9 It's August 5th, Roy's 52nd birthday. The cake has been baked, the presents wrapped. But Roy just doesn't feel like celebrating. His family and friends know him as active, outgoing and ambitious. He's VP of Purchasing for an electronics firm, he coaches his son's hockey team and he's the one who gets the call when there's a charity car wash to organize. His wife Ellen has always been his best friend. Their lives revolve around teenaged kids and friends. There are dinner parties, outings, and on weekends he plays tennis or works on his 9 handicap.
But lately, Roy has not "been himself". He always feels used up at the end of the day. The old drive is missing. After dinner, all he can think about is hitting the sofa with the remote, often dozing right there. His relationship with Ellen has also been strained. They often argue now and he tends to just clam up more. He doesn't feel much like having sex anymore either. In fact, it's been weeks now.
At work, he feels oddly threatened by his bright new assistant who would obviously like his job. He no longer feels so sure of himself or his future. His co-workers have noticed that he is edgy and often unreasonable in his de-mands. "The golf game tomorrow? How can I get out of it? I'm just too tired to go. I just don't have the same enthusiasm for things. Ah, I don't know, I must be getting old." (http://www.andropause.com) Roy's story contains all the elements of what, in earlier incarnations, defined midlife crisis-despite the outward markers of a successful, Western, middle-class life (happy marriage, children, career, respect in the community, a decent golf handicap), Roy has an inner dissatisfaction, anxiety, and decline in libido. However, where once the midlife crisis, understood as a generalized change of life, might have seen Roy's complaints as requiring primarily psychosocial adjustments to the aging process, the reader here is invited to self-assess their risk for androgen deficiency. Clicking on the "assess your risk" button leads to a quiz: NOTE: A positive questionnaire result is defined as a "yes" answer to questions 1 or 7 or any other three questions (Morley et al. , 1240 . This is the ADAM (Androgen Decline in the Aging Male) questionnaire, developed and tested by a team based at the University of St. Louis and at Organon who claim that the ADAM questionnaire is a useful clinical screening tool that "identifies a symptom complex associated with the age-related decline in testosterone that may be amenable to therapeutic intervention" (Morley et al. , 1239 . Andropause reinvented as ADAM not only groups a variety of somewhat vague symptoms into a complex or syndrome but links them to a specific etiology (androgen decline). The foregrounding of erectile dysfunction as a symptom of andropause appears more related to the post-Viagra willingness of men to present with this disorder than it does to any evidence linking erectile dysfunction to low testosterone levels.
10 As Dunsmuir (1999, 138) suggests, "Much of the lay public equates the male menopause with erectile failure" even though studies of men presenting with erectile dysfunction at clinics show that the incidence of abnormal endocrine profiles in this group is quite low (Johnson and Jarow 1992; T'Sjoen et al. 2003) . In the Massachusetts Male Aging Study, a large community-based study, no significant correlations between testosterone levels and erectile dysfunction were reported (Feldman et al. 1994 ). Yet the ADAM questionnaire treats a positive response to the question about erectile dysfunction as immediately identifying the respondent as "at risk" for androgen deficiency. In the post-Viagra climate, which has raised public awareness of the risk of sexual decline with aging, the notion of andropause as a widespread disorder circulates through the scientific literature, the clinic, and the general public by way of citation, marketing, and the lay media.
Despite controversies, the existence of ADAM has now become reiterated as fact, and physicians are made newly responsible for screening their patients "by routinely asking about libido, sexual function and stamina in their systems assessment. An alternative is to use a simple questionnaire that patients can fill out in the waiting room" (MacIndoe 2003, 52) . In ads directed at physicians, such as one appearing in medical journals from Watson Pharmaceuticals, the makers of Androderm, the ADAM study is cited to underscore the need for doctors to screen their patients. "Testosterone Deficiency is Underdiagnosed and Undertreated-Even Among Physicians!" shouts the headline, and the text tells doctors that "screening may benefit millions." The ad recommends completion of the ADAM questionnaire, followed by a blood testosterone test for those it identifies as at risk.
Mainstream mass media and Internet health sites have been key sources of public information on the new sexual science and, hence, important as conduits for disseminating scientific and medical knowledge to the general public (Braun et al. 2000; Conrad 2005; Wyatt et al. 2004 ). This is critical in a social context where individuals are increasingly called upon to be health literate and equipped with the necessary knowledge to take appropriate actions regarding their own well-being (Chrysanthou 2002; Henwood et al. 2003; Petersen and Lupton 1996; Pryce 2000) . Direct-to-consumer advertising, permitted in some countries like the United States and New Zealand, constructs the individual as a key agent in the diagnosis and treatment of disease. Thus, men are encouraged to screen themselves and consult their doctorsan advertisement from the makers of Androgel, widely circulated in magazines such as Men's Health and Golf, warns men that they might be "running on empty" and encourages them to take a simple quiz (again, the ADAM questionnaire). At rough count, this quiz is reproduced on more than 150 health-information Web sites and in numerous newspaper and magazine stories about andropause (see, e.g., "Take the Quiz" 2002).
Mainstream media stories are frequently the result of pharmaceutical company press releases highlighting public education campaigns or new products for testosterone replacement. For example, the introduction of transdermal gels for the delivery of testosterone prompted a flurry of press coverage, with such articles as "Keeping the Drive Alive" (Kirkey 2003) , "It's the Men's Turn Now: Hormone Replacement Therapy Turns Its Attention to Males" (Uhlenhuth 2003) , "Hormone-deficient Men Deserve a Little Sympathy" (Black 2001) , and "New Testosterone Gel Rubbing Men the Right Way" (Priest 2002) , appearing in major mass media outlets. These stories follow a familiar script that generally gives the impression that while the existence of male menopause has been a subject of controversy in the past, new scientific evidence has created a new consensus that it does, in fact, exist and is treatable with hormone-replacement therapy. While there is generally a brief nod given to the fact that not all scientists endorse the construction of andropause as a disease and to possible risks of testosterone therapy, such as prostate cancer, these concerns pale beside the stories of miraculous transformations (weight loss, muscle gain, better sex, better mood) wrought by diagnosis and treatment of andropause-as-hypogonadism that form the backbone of every article. And nowhere is the recentering of sexual function more evident-as one article stressed for its readers who might think that erectile dysfunction was their only problem, "If you think you can Viagra your way out of this one, think again: It and similar drugs might help with the mechanics, but not with desire; testosterone is what fires the libido" (Werland 2004, 9) .
A doctor with a men's clinic recounts a typical success story, involving a forty-year-old complaining about erectile dysfunction and low libido. After he "treated the erectile dysfunction and prescribed oral testosterone for the man's low libido," the patient returned after six weeks. "He was vibrant. He had quit his job and gone into business for himself-something he said that he always wanted to do but never believed in himself enough to follow through. . . . The man's marriage was wonderful and his sex life was great. He had a great sense of vitality and a positive attitude towards life" (Powell 2000, D2) . This example is particularly striking in its linking of treatments for erectile dysfunction (presumably Viagra) and diminished libido (testosterone). But even more striking is the manner in which sexual decline and its reversal are linked, just as in the early rejuvenation movement, with the restoration of men's productive powers more generally.
Whether in clinical journals, health-information Web sites, or newspaper headlines, the very reiteration of ADAM as news confirms it as "real," even when alternative perspectives are presented. For example, Dr. John McKinlay, one of the directors of the Massachusetts Male Aging Study, was recently covered in the British press for his assertions that "the male menopause is a myth and men who claim to suffer from it may simply be overweight or drinking too much" (Frith 2003, 6 ). In the same article, though, Dr. Malcolm Carruthers, a high-profile andropause promoter, is given the last word: "I see men who come into my surgery with classic symptoms of the andropause. They are underperforming in the bedroom and the boardroom, their marriages are falling apart and they are in a depressive state. Once they go on the HRT, they do get better. . . . There is overwhelming scientific evidence that the andropause does exist" (Frith 2003, 6) .
There are parallels here between the construction and promotion of andropause as a disorder with testosterone as its treatment and the construction and promotion of other disorders and treatments, such as depression (Gardner 2003) , social anxiety disorder (Healy 2001) , and female sexual dysfunction (Tiefer 2001) . For example, Gardner (2003) , in her analysis of the marketing of depression-as-illness and its treatment by psychotropic drugs, also finds highly contentious theories masquerading as fact and a "common-sense script" of the disease constructed, which is "difficult for consumers to think outside of" (p. 106). Controversial and contested theories are translated into scientific facts, and a worldview that favors "magic bullets" is fostered. Under the guise of "empowering" the individual, dysfunctions demand correction through the consumption of appropriate remedies.
CONCLUSIONS: MEDICALIZING THE AGING MALE BODY
In this article, I have argued that shifting cultural narratives, rather than any new scientific "discoveries," have fostered the (re)medicalization of the male menopause. Aging men are now exhorted to be "forever functional" (Marshall and Katz 2002) . As Calasanti and King (2005, 16) summarize, "sexual function now serves as a vehicle for reconstructions of manhood as 'ageless'. . . . To the extent that men can demonstrate their virility, they can still be men and stave off old age and the loss of status that accrues to that label."
Not surprisingly, the clinical and market success of Viagra has been critical in the development of a men's health industry, creating novel discursive and institutional structures that have fostered the medicalization of masculinity in later life. Viagra solidified a turn to understanding the aging male body as a series of functional subsystems amenable to constant monitoring and biotechnical intervention. While Viagra was seen as the solution to malfunction in one of these subsystems (vascular flow to the penis), the problems of the aging male were now increasingly opened up to diagnosis and treatment. That there is profit to be made here cannot be denied-according to industry reports, the therapeutic areas of sexual dysfunction and male menopause are expected to lead the way in expanding the already $17 billion world market in pharmaceuticals for "men's health" (Biotech Week, September 10, 2003, 289) .
Male menopause reconfigured as ADAM, a systematic disorder of androgen deficiency, reinvigorates a discourse of biologically based, lifelong, sexual difference. Not unlike the "feminine forever" message with which women were bombarded by proponents of hormone-replacement therapy in the 1960s, the newly remedicalized climacteric in men reasserts a hormonal basis for masculinity itself. Decline in sexual virility, sports performance, work success-these all become markers of the equation of aging with de-masculinization.
As Gail Vines has argued, the scientific and medical discourse on hormones is not just about a variety of biochemicals: "Time and again, hormones also seem to be standing in for something else." They are "loaded with powerful symbolic meanings that reflect a remarkable array of shifting, and often conflicting, social and cultural preoccupations" (Vines 1994, vii) . What is this "something else" in the case of testosterone? In a manner reminiscent of the rejuvenation science of the 1920s, the reinvented male menopause crystallizes anxieties over aging in terms of biochemical de-masculinization. Not only sexual function but masculine vitality itself is at stake in biological decline. No correlate of "normality" is required here, only "functionality"-in fact, what might be statistically normal is redefined as dysfunctional.
11 As Dr. William Crowley, a critic of the andropause industry, asks, "When you elevate the testosterone levels in a seventy-year-old man to those he had at twenty, are you really returning him to 'normal'?" (cited in Groopman 2002, 7) .
The authors of the Massachusetts Male Aging Study caution that the medicalization of normally aging men raises both ethical and public health challenges, especially in the wake of what we have learned from the risks of HRT in women (O'Donnell et al. 2004) . I suggest that it also raises theoretical challenges for those of us interested in the construction of gender across the life course and especially in theorizing masculinity. Gendered bodies are at the same time sexual bodies and aging bodies, and it is at this convergence that this article is located. The specific case of the medicalization of the male menopause in the late twentieth and early twenty-first centuries illustrates the manner in which such bodies are made and remade at the intersections of science and culture.
The search for a biochemical basis to masculinity is also a clear example of a cultural tendency to locate gender more deeply within the body, more resolutely presocial, and less open to contestation.
12 In exposing and critiquing the association of masculinity itself with some hypostatized and naturalized male body, we have an opportunity to redirect attention to the social relations that construct gender, relations that include age among other factors. Age poses problems to conceptions of hegemonic masculinity, and as long as "old men retain status only to the extent that they appear to be like younger, heterosexual men" (Calasanti 2004, S312) , the lure of a chemical fix will remain potent. A challenge to cultural narratives of age and decline, which prescribe narrow standards of functionality-sexual and otherwise-as markers of successful aging should thus become part of our critique of the social construction of masculinity.
NOTES
1. The Women's Health Initiative was a fifteen-year, multifaceted research study, launched by the National Institute of Health in 1991, to assess risks to health among postmenopausal women. For further information, see its Web site at http://www.nhlbi.nih.gov/whi/background .htm.
2. This article reports on research that is part of a much larger project on the medical management of heterosexual function since the nineteenth century. Qualitative document analysis, assisted by NVIVO, a qualitative research software program, has been undertaken on a large inventory of texts, including clinical research published in medical journals, historical and contemporary medical textbooks, popular health reporting in newspapers, magazines, books, Web sites, and pharmaceutical industry promotional and educational materials. Clinical research was located using Medline, a computerized index of medical research, and popular media articles were located with media search engines LexisNexis, Gale Information, and the Canadian Periodicals Research Index. Historical research was done at the Wellcome Institute for the History of Medicine, the British Library, and the Kinsey Institute. The research reported here on the contemporary construction of the male menopause draws on approximately one hundred clinical research articles, thirty-five popular media articles, and twelve Web sites.
3. For further discussion of the relationship between organotherapy and mainstream medicine, see Borell (1976 ), Jahiel (1992 , Oudshoorn (1994) , and Sengoopta (2001) .
4. Testosterone did not, however, become successful as a mass-market drug in the 1940s, which Hoberman (2005, 104) attributes to the "sexual conservatism" of both the medical profession and the general public.
5. For extended discussion of Viagra and its role in reconceptualizing the sex-age relationship, see Marshall (2002, forthcoming) and Marshall and Katz (2002, forthcoming) .
6. Hypogonadism is a condition characterized by inadequate gonadal function or pituitarygland malfunction, caused by surgery, liver or kidney disease, infections, injury, radiation, or genetic disorders and is generally diagnosed on the evidence of symptomatic complaints in the presence of abnormally low testosterone levels.
7. Many of the citations on andropause are review articles, representing little in the way of new research.
8. For example, it has been noted that many studies have small sample sizes, lack placebo controls, use varying measures of testosterone levels, have nonrepresentative samples, and fail to screen for possibly confounding factors, such as lifestyle variables (smoking, alcohol use, stress, drug use) or concurrent disease (Liverman and Blazer 2004; Metz and Miner 1995) .
9. These include the Web site of the Canadian Andropause Society (http://www .andropausesociety.ca), which is ostensibly a health-information site provided by a professional medical association.
10. According to the authors of the study validating the questionnaire, "the most common affirmative answer for individuals with low BT was in response to question 7 pertaining to the strength of penile erections" (Morley et al. , 1240 ). Yet there is no evidence to link these two factors in any causal relation.
11. See Katz and Marshall (2004) for elaboration of the argument that "functionality" has replaced "normality" in recent biomedical discourse.
12. This same tendency can be seen, for example, in the popularity of "evolutionary psychology" in explaining gender difference and in the search for a biological explanation for sexual orientation. For more general critiques, see Fausto-Sterling (2000) and Rose and Rose (2000) .
